AOA dx
A revolutionary
way to save half the women diagnosed with Ovarian Cancer
Scroll down to discover the future
Akrivis GD
TM
The first liquid biopsy test that accurately enables early diagnosis of ovarian cancer through the analysis of tumor marker gangliosides.
We are
AOA.
AOA Dx is a team of entrepreneurs and experts that brings innovative, impactful and cost-effective medical technologies from research and development into the hands of providers and patients.
The co-founders have worked together for a decade at two successful women's health diagnostic startups, resulting in large strategic exits. to commercialization across global markets.
Learn more about our mission and company
More than 90% of new discoveries in medical innovation stay in research within an academic setting and are never commercialized and widely adopted to help patients.
We want to change that.
MEET THE TEAM
A team of innovators who have successfully brought paradigm changing diagnostics to market.
INVESTORS
Do you want to be a part of innovating the next class of markers in early cancer detection?
We would love to hear from you and work together on creating a more innovative, efficient and patient-oriented future.
"Our goal is to work closely with scientific innovators to make their products widely available to impact clinical practice today"
What's next?
AOA is pioneering the field of Glycomics, a new frontier in diagnostics.
Get up-to-date information about our pipeline.
Featured In
